All together, the expected hazard of graft failure was estimated according to recipient age and gender, causal nephropathy, comorbidities (including history of diabetes, hypertension, cardiac or vascular disease, dyslipemia, hepatitis B or C, and malignancy), obesity, pre-transplant immunization (panel reactive antibody, PRA) against class I and class II antigens), donor age, deceased or living donor status, Epstein-Barr Virus (EBV) serology, period of transplantation, level of HLA-A-B-DR mismatches, induction therapy and cold ischemia time. Here, HLA-A is linked to hepatitis B virus infection.